Dexamethasone nanomedicines for COVID-19

Twan Lammers; Alexandros Marios Sofias; Roy van der Meel; Raymond Schiffelers; Gert Storm; Frank Tacke; Steffen Koschmieder; Tim H. Brümmendorf; Fabian Kiessling; Josbert M. Metselaar

doi:10.1038/s41565-020-0752-z

journal article·2020-08Open access

Dexamethasone nanomedicines for COVID-19

Twan Lammers, Alexandros Marios Sofias, Roy van der Meel, Raymond Schiffelers, Gert Storm, Frank Tacke, Steffen Koschmieder, Tim H. Brümmendorf, Fabian Kiessling, Josbert M. Metselaar

Nature Nanotechnology· Volume 15· Issue 8

Publisher page Open full text

Source abstract

Abstract

Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

Source: openaire · Quality: candidate unverified · Source record ↗

Research context

Nanomaterials

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Nanoplatforms for cancer theranostics · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (19)

Show source-provided references

1. Results. RECOVERY Trial https://www.recoverytrial.net/results (2020)

2. Horby, P. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020)10.1056/NEJMoa2021436 ↗

3. Villar, J. et al. Lancet. Respir. Med. 8, 267–276 (2020).10.1016/S2213-2600(19)30417-5 ↗

4. Ledford, H. Nature https://doi.org/10.1038/d41586-020-01824-5 (2020).10.1038/d41586-020-01824-5 ↗

5. Merad, M. & Martin, J. C. Nat. Rev. Immunol. 20, 355–362 (2020).10.1038/s41577-020-0331-4 ↗

6. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. T. Nat. Rev. Immunol. 20, 363–374 (2020).10.1038/s41577-020-0311-8 ↗

7. Quan, L. et al. ACS Nano 8, 458–466 (2014).10.1021/nn4048205 ↗

8. Banciu, M., Metselaar, J. M., Schiffelers, R. M. & Storm, G. J. Steroid Biochem. Mol. Biol. 111, 101–110 (2008).10.1016/j.jsbmb.2008.05.004 ↗

9. Crielaard, B. J. et al. Int. J. Pharm. 416, 499–506 (2011).10.1016/j.ijpharm.2010.12.045 ↗

10. Bartneck, M. et al. Biomaterials 37, 367–382 (2015).10.1016/j.biomaterials.2014.10.030 ↗

11. Kroon, J. et al. Prostate 75, 815–824 (2015).10.1002/pros.22963 ↗

12. Gauthier, A. et al. Biomaterials 178, 481–495 (2018).10.1016/j.biomaterials.2018.04.006 ↗

13. Deshantri, A. K. et al. J. Control. Release 296, 232–240 (2019).10.1016/j.jconrel.2019.01.028 ↗

14. A evaluation of the safety of Oncocort IV pegylated liposomal dexamethasone phosphate in patients with progressive multiple myeloma. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03033316 (2017).

15. Zhang, J. et al. Front. Microbiol. 9, 915 (2018).10.3389/fmicb.2018.00915 ↗

16. Metselaar, J. M., Wauben, M. H. M., Wagenaar-Hilbers, J. P. A., Boerman, O. C. & Storm, G. Arthritis Rheum. 48, 2059–2066 (2003).10.1002/art.11140 ↗

17. George, P. M., Wells, A. U. & Jenkins, R. G. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(20)30225-3 (2020).10.1016/S2213-2600(20)30225-3 ↗

18. Kaier, K., Heister, T., Wolff, J. & Wolkewitz, M. BMC Health Serv. Res. 20, 267 (2020).10.1186/s12913-020-05133-5 ↗

19. Dasta, J., McLaughlin, T., Mody, S. & Piech, C. Crit. Care Med. https://doi.org/10.1016/S2213-2600(20)30225-3 (2005).10.1016/S2213-2600(20)30225-3 ↗